Private Placement

The semiconductor equipment firm will release crucial 2025 and 2026 financial guidance in January, offering a key early test of the industry's momentum.

A private tender offer values diagnostics firm PathoCare at $1.75B. Can its AI-powered, non-invasive technology justify the price and transform medicine?

The National Police Federation slams a report backing a provincial police force, citing high costs, low public support, and broken promises.

Commodity giant Mercuria secures copper and gold from Pucobre's El Espino mine with a $375M financing deal, betting big on Chile and green metals.

With a novel therapy from newborn heart cells, Secretome Therapeutics heads to J.P. Morgan to showcase its progress against intractable heart failure.

UnifyDrive's new UP6 combines a NAS, AI, a touchscreen, and a UPS, creating a new device category that could end laptop dependency for creators.

With promising survival data and a pivotal Phase 3 trial underway, Imunon's localized immunotherapy could finally change the game for ovarian cancer.

A successful demonstration of Revoltz's compact electric cargo vehicle to Israeli officials could signal a major shift in last-mile logistics.

Mixed Martial Arts Group lands $3 million in funding, with Donald Trump Jr. investing, to fuel its ambitious blockchain-based fan engagement platform.

Tired of ads and algorithms? Gistvox has launched an audio-only app with a radical idea: intentional listening. But can its unique business model survive?

A CETY affiliate moves its 2.2 MW Vermont plant through regulatory hurdles, but past setbacks, new technology, and financial questions loom large.

After retiring $1.4M in toxic debt, QHSLab has secured fresh equity to scale its AI-driven primary care platform, marking a pivotal turnaround.

As its cash runway shortens, Longeveron's novel stem cell therapy gets a major boost with selection for a prestigious Alzheimer's health moonshot.

The AI investment frenzy is shifting from GPUs to the physical world of power, cooling, and real estate, creating a new class of high-value companies.

With a promising schizophrenia drug stalled by FDA requirements and finances tight, Reviva Pharmaceuticals' upcoming presentation is more than just a talk.

Bluejay Diagnostics can now make 9 million sepsis tests. This manufacturing win is huge, but the real race for FDA approval has only just begun.

Capital Square launches a new DST for a Richmond senior community, capitalizing on demographic shifts and the city's powerful economic growth.

A deepened strategic alliance sees mobility tech provider ECARX invest in Lotus, aiming to accelerate the future of the intelligent, AI-driven cockpit.

With a massive IDR 200 billion capital boost from LDA Capital, Indonesian tech firm NANO is set to execute nearly IDR 5 trillion in contracts.

Adlai Nortye licenses its promising pan-RAS cancer inhibitor to ASK Pharm for Greater China in a deal valued at up to $230 million.